Spevigo (spesolimab-sbzo) / Boehringer Ingelheim, LEO Pharma - LARVOL DELTA

Long-term (≥3 year) efficacy and safety of subcutaneous spesolimab for treatment of generalized pustular psoriasis: Results from the EFFISAYIL program (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Intravenous spesolimab for (re)treatment of generalized pustular psoriasis flares in patients receiving subcutaneous spesolimab: Results from the 5-year, open-label, EFFISAYIL ON extension study (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Long-term disease control with subcutaneous spesolimab in GPP patients with or without IL-36RN mutation. Results from the EFFISAYIL ON study (EADV 2026) - No abstract available

Clinical • Dermatology • Inflammation

Rapid improvement of systemic inflammatory markers by spesolimab in generalized pustular psoriasis: a real-world daily time-course analysis (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Treatment of SAPHO Syndrome with Spesolimab: A Case Report (EADV 2026) - No abstract available

Case report • Clinical

Pustular dermatoses (EADV 2026) - "APF is a rare, chronic, relapsing disease of folds often associated with autoimmunity and treated variably with dapsone, cyclosporine, colchicine and, in recent reports, biologics such as spesolimab. Prof. Angelo Valerio Marzano Full Professor of Dermatology and Head Dermatology Unit , Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy Past Director of the Residency Program in Dermatology and Venereology Università degli Studi di Milano, Milan, Italy Voluntary Professor of Dermatology, Miller School of Medicine, University of Miami, Florida, USA"

Dermatology • Immunology • Psoriasis • Pustular Psoriasis • Rare Diseases

Spesolimab in Pregnancy: A Breakthrough Treatment for Coexisting Generalized Pustular Psoriasis and Hallopeau Acrodermatitis Continua. (PubMed, Am J Ther) - No abstract available

Journal • Dermatitis • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Real-world safety profile of spesolimab in generalised pustular psoriasis: expanded access programmes in Japan, China and Argentina. (PubMed, Br J Dermatol) - No abstract available

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Early Temporal Dissociation Between C-Reactive Protein and Neutrophil Counts After Spesolimab Treatment in Generalized Pustular Psoriasis. (PubMed, Acta Derm Venereol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis • Pustular Psoriasis • CRP

Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis. (PubMed, Pragmat Obs Res) - "IL-36R inhibitors, such as spesolimab, are potentially effective and safe treatment for both adolescent and adult patients with GPP. Future studies should explore the long-term efficacy of spesolimab and its application strategy of sustained disease control."

Journal • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis • Pustular Psoriasis

Spesolimab for treatment of generalized pustular psoriasis of pregnancy. (PubMed, Pregnancy (Hoboken)) - "Her disease was refractory to high-dose glucocorticoids, cyclosporine and TNF-α inhibitors. This is the first published use of spesolimab in a pregnant patient in the United States. We suggest that spesolimab may offer rapid, safe relief of severe immunologic disease in pregnancy, though further study is required."

Journal • Cardiovascular • Critical care • Dermatitis • Dermatology • Diabetes • Fatigue • Hypertension • Immunology • Psoriasis • Pustular Psoriasis

Clinical Practice Recommendations for Non-Dermatologists on the Diagnostic Suspicion of GPP. (PubMed, J Clin Med) - "For these reasons, multidisciplinary round-table discussions and shared diagnostic and therapeutic algorithms involving dermatologists, who are responsible for diagnosing and treating GPP, and other medical specialists are desirable to facilitate prompt referral to dermatologists for accurate diagnosis and appropriate treatment. We report the updated literature discussed during a multidisciplinary meeting with the aim of providing practice recommendations for clinicians involved in GPP management."

Journal • Review • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Pain • Pruritus • Psoriasis • Pustular Psoriasis • Septic Shock

Population pharmacokinetics and exposure-response modelling to inform spesolimab dosing regimen in generalised pustular psoriasis (EADV 2026) - No abstract available

Clinical • PK/PD data • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

When Conventional Therapy Fails: Interleukin-36 Inhibition for Severe Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis in Systemic Lupus Erythematosus - A Case Report. (PubMed, Case Rep Dermatol) - "Acute generalized exanthematous pustulosis (AGEP) is a rare but severe cutaneous adverse drug reaction characterized by the sudden onset of widespread sterile pustules on an erythematous and edematous base, often accompanied by fever and neutrophilia. Crosstalk between IL-36 signaling and neutrophil extracellular traps may amplify inflammation, linking AGEP with autoimmune pathology. IL-36 inhibition with spesolimab represents a potential rescue therapy for severe, treatment-refractory AGEP, particularly in patients with underlying autoimmune disorders where conventional therapies fail."

Journal • Cutaneous Lupus Erythematosus • Dermatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus

Genotype-Phenotype Correlations and Clinical Outcomes of Spesolimab in Acrodermatitis Continua of Hallopeau: A Multicenter Retrospective Cohort Study. (PubMed, Psoriasis (Auckl)) - "Relapse occurred in 4 patients between weeks 31 and 44, with disease activity remaining lower than baseline and improvement observed after re-treatment. Spesolimab was associated with clinical improvement in refractory ACH with biallelic IL36RN mutations, including isolated ACH treated with a 450-mg dose, supporting further evaluation of dose individualization below the approved 900-mg regimen for GPP flares."

Clinical data • Journal • Retrospective data • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • Pustular Psoriasis

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (clinicaltrials.gov) - P3 | N=90 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P3 trial • Dermatology • Pyoderma Gangrenosum

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Feb 2028 ➔ Aug 2028 | Trial primary completion date: Apr 2027 ➔ Nov 2027

Trial completion date • Trial primary completion date • Dermatology • Pyoderma Gangrenosum

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis Who Need Treatment for Repeated Flares (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis Who Need Treatment for Repeated Flares (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P4 trial • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares (clinicaltrials.gov) - P4 | N=42 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Apr 2027 ➔ Nov 2026 | Trial primary completion date: Dec 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares (clinicaltrials.gov) - P4 | N=40 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Pyoderma Gangrenosum

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Boehringer Ingelheim | Trial completion date: Oct 2027 ➔ Feb 2028 | Trial primary completion date: Dec 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Dermatology • Pyoderma Gangrenosum

Free Flap Management in Patients with Uncontrolled Psoriasis: Insights from a Case Series (AHNS 2026) - "One patient started Spesolimab infusions after being discharged from the hospital (Subject 3) with complete resolution of symptoms... Here, we present three patients with inadequately controlled psoriasis who underwent successful free tissue transfer with no adverse surgical site or free flap outcomes, suggesting the inflammatory state due to psoriasis is not a contraindication to proceeding with this surgery. This does highlight the need for careful peri-operative management and patient counseling, as well as multi-disciplinary care including involvement of dermatology colleagues for acute and long-term management."

Clinical • Dermatology • Head and Neck Cancer • Immunology • Infectious Disease • Psoriasis • Solid Tumor • Squamous Cell Carcinoma

Resolution of life- and limb-threatening pyoderma gangrenosum with spesolimab. (PubMed, JAAD Case Rep) - No abstract available

Journal • Dermatology • Pyoderma Gangrenosum